The results showed a higher chromatin accessibility of KLHL42 in malignant CD4+ T cells (clusters 1, 2, and 5) from the SS patient than in benign CD4+ T cells (cluster 4) from HCs (Fig. 5D, E), indicating that the KLHL42 expression was regulated by epigenetic modification. This evidence concerns the gene KLHL42 and synovial sarcoma.